|
biomedicina slovenica |
pr=Bedard : 15
-
Veitch Zachary; Ribnikar Domen; Tilley Derek; Tang Patricia; King Karen; Bedard Philippe L.; Lupichuk Sasha; Cescon David W.
No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer
2022 ►
-
Ribnikar Domen; Stukalin Igor; Bedard Philippe L.; Hamilton Robert J.; Jewett Michael; Warde Padraig; Chung Peter; Templeton Arnoud J.; Amir Eitan; Lewin Jeremy
The prognostic value of neutrophil-to-lymphocyte ratio in metastatic testicular cancer
2020 ►
-
Ribnikar Domen; Bedard Philippe L.
Utility of molecular tools for extended adjuvant endocrine therapy decisions in early breast cancer
2017 ►
-
Vera-Badillo Francisco Emilio; Chang Martin; Kuruzar Gordana; Ocaña Alberto; Templeton Arnoud J.; Šeruga Boštjan; Goldstein Robyn; Bedard Philippe L.; Tannock Ian; Amir Eitan
Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer
2015 ►
-
Tibau B.; Bedard Philippe L.; Vera-Badillo Francisco Emilio; Templeton Arnoud J.; Ocaña Alberto; Šeruga Boštjan; Barnadas Agustí; Amir Eitan
Author financial conflicts of interest (FCOIs) in clinical practice guidelines (CPGs) for systemic anti-cancer drugs
2014 ►
-
Tibau Ariadna; Bedard Philippe L.; Srikanthan Amirrtha; Ethier Josee-Lyne; Vera-Badillo Francisco Emilio; Templeton Arnoud J.; Ocaña Alberto; Šeruga Boštjan; Barnadas Agustí; Amir Eitan
Author financial conflicts of interest, industry funding, and clinical practice guidelines for anticancer drugs
2015 ►
-
Vera-Badillo Francisco Emilio; Chang Martin; Kuruzar Gordana; Ocaña Alberto; Templeton Arnoud J.; Šeruga Boštjan; Al-Mubarak Mustafa; Goldstein Robyn; Bedard Philippe L.; Tannock Ian; Amir Eitan
Association between androgen receptor (AR) expression, Ki-67, and the 21-gene recurrence score in early breast cancer
2014 ►
-
Amir Eitan; Šeruga Boštjan; Ocaña Alberto; Carlsson Lindsay; Bedard Philippe L.
Pooled analysis of outcomes of T1a/bN0, HER2-amplified breast cancer
2011 ►
-
Pezzo R. C.; Šeruga Boštjan; Krzyzanowska M. K.; Bedard Philippe L.
Quality of safety reporting in oncology-randomized controlled trials (RCTs)
2011 ►
-
Vera-Badillo Francisco; Templeton Arnoud J.; Gouveia Paulo de; Diaz-Padilla Ivan; Bedard Philippe L.; Al-Mubarak Mustafa; Šeruga Boštjan; Tannock Ian; Ocaña Alberto; Amir Eitan
Androgen receptor expression and outcomes in early breast cancer
2013 ►
-
Vera-Badillo Francisco; Templeton Arnoud J.; Gouveia Paulo de; Diaz-Padilla Ivan; Bedard Philippe L.; Al-Mubarak Mustafa; Šeruga Boštjan; Tannock Ian; Ocaña Alberto; Amir Eitan
Androgen receptor expression and outcomes in early breast cancer
2014 ►
-
Templeton Arnoud; Ocaña Alberto; Šeruga Boštjan; Vera-Badillo Francisco; Carlsson Lindsay; Bedard Philippe L.; Amir Eitan
Management of small HER2 overexpressing tumours
2012 ►
-
Amir Eitan; Bedard Philippe L.; Ocaña Alberto; Šeruga Boštjan
Benefits and harms of detecting clinically occult breast cancer
2012 ►
-
Snoj Nataša; Bedard Philippe L.; De Azambuja Evandro; Cardoso Fatima; Piccart Martine
Are we HER-ting for innovation in neoadjuvant breast cancer trial design?
2009 ►
-
Cardoso F; Bedard PL; Winer EP; Pagani O; Senkus-Konefka E; Fallowfield LJ; Kyriakides S; Costa A; Čufer T; Albain KS
International Guidelines for Management of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy
2009 ►
New search
Comments
Top of page
Institute for Biostatistics and Medical Informatics